Medicaid and Children's Health Insurance Program (CHIP) Generic Information Collection Activities: Proposed Collection; Comment Request, 58741-58743 [2024-15882]
Download as PDF
<![CDATA[
58741
Federal Register / Vol. 89, No. 139 / Friday, July 19, 2024 / Notices
Proposed Project
Evaluation of an Online Prostate
Cancer Decision Aid—New—National
Center for Chronic Disease Prevention
and Health Promotion (NCCDPHP),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
The Centers for Disease Control and
Prevention (CDC), Division of Cancer
Prevention and Control (DCPC) is
requesting a new, three-year OMB
approval to conduct a three-arm,
randomized controlled trial (RCT) to
evaluate the impact of a virtual human
decision aid to help improve the quality
of prostate cancer screening and
treatment decisions. Talk to Nathan
About Prostate Cancer Screening
(hereafter referred to as Nathan) is
DCPC’s online, interactive, human
simulation decision aid designed to
help men learn and make informed
decisions about prostate cancer
screening. A small, preliminary
evaluation of Nathan showed promise in
increasing men’s knowledge about
prostate cancer and likelihood of
engaging in shared decision-making
about prostate cancer screening with
their health care providers. At this time,
a larger, more systematic evaluation can
help to understand whether Nathan is
effective in areas such as improving
knowledge, overcoming health literacy
barriers, and resolving decisional
conflict, especially among priority
populations who are most likely to be
affected by prostate cancer and least
likely to be screened. Further, as some
experts consider the digital divide to be
the newest social determinant of health,
it is important to explore how, where,
and for which populations there may be
disparities in accessing and using
Nathan.
Broadly, the purpose of this
information collection is to: (1) assess
whether Nathan is more effective at
helping men make decisions about
prostate cancer screening than an
established decision aid or standard
educational materials; (2) determine if
changes or improvements to Nathan are
warranted; and (3) identify ways to
incorporate Nathan into primary care.
We will select four primary care clinics
to participate in this study. The RCT
includes a three-group parallel design
with one treatment arm and two control
arms to test the effectiveness of Nathan
for men aged 55–69. We will recruit 900
men aged 55–69 who have an upcoming
general health exam at one of the four
primary care clinics and randomize
them to one of three arms: (1) Nathan
(intervention = 300 men); (2) the
Massachusetts Department of Public
Health’s (MDPH’s) Patient Decision Aid,
Get the Latest Facts about Screening for
Prostate Cancer (control 1 = 300 men);
and (3) standard educational materials
from the National Cancer Institute (NCI),
Prostate Cancer Screening (PDQ®)—
Patient Version (control 2 = 300 men).
Eight forms of information collection
will be implemented to answer our
evaluation questions. These include a
provider survey; a patient eligibility
screener; patient pre-exposure, postexposure, and post-clinic visit surveys;
a patient usability survey; patient user
experience interviews; and clinic
coordinator interviews. Each instrument
will be administered once per
respondent throughout the course of the
study. The provider survey and clinic
coordinator interviews will be
conducted in English only. All other
information collections will be
conducted in English or Spanish. The
total response burden is estimated to be
1,129 hours. There are no costs to
respondents other than their time to
participate in data collection activities.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondents
Form name
Primary care providers ....................................
Men ages 55–69 .............................................
Men ages 55–69 .............................................
Men ages 55–69 .............................................
Men ages 55–69 .............................................
Men ages 55–69 .............................................
Men ages 55–69 .............................................
Clinic coordinators ..........................................
Provider survey ..............................................
Patient eligibility screener ..............................
Pre-exposure survey ......................................
Post-exposure survey ....................................
Usability survey ..............................................
User experience interview ..............................
Post-clinic survey ...........................................
Clinic coordinator interview ............................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2024–15965 Filed 7–18–24; 8:45 am]
[Document Identifier: CMS–10434 #66]
Centers for Medicare & Medicaid
Services
ddrumheller on DSK120RN23PROD with NOTICES1
BILLING CODE 4163–18–P
Medicaid and Children’s Health
Insurance Program (CHIP) Generic
Information Collection Activities:
Proposed Collection; Comment
Request
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
AGENCY:
On May 28, 2010, the Office
of Management and Budget (OMB)
SUMMARY:
VerDate Sep<11>2014
18:53 Jul 18, 2024
Jkt 262001
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
40
900
900
900
300
30
900
4
Number of
responses per
respondent
1
1
1
1
1
1
1
1
Average
burden per
response
(in hours)
10/60
8/60
20/60
20/60
18/60
20/60
20/60
30/60
issued Paperwork Reduction Act (PRA)
guidance related to the ‘‘generic’’
clearance process. Generally, this is an
expedited process by which agencies
may obtain OMB’s approval of
collection of information requests that
are ‘‘usually voluntary, low-burden, and
uncontroversial collections,’’ do not
raise any substantive or policy issues,
and do not require policy or
methodological review. The process
requires the submission of an
overarching plan that defines the scope
of the individual collections that would
fall under its umbrella. This Federal
Register notice seeks public comment
on one or more of our collection of
information requests that we believe are
generic and fall within the scope of the
E:\FR\FM\19JYN1.SGM
19JYN1
ddrumheller on DSK120RN23PROD with NOTICES1
58742
Federal Register / Vol. 89, No. 139 / Friday, July 19, 2024 / Notices
umbrella. Interested persons are invited
to submit comments regarding our
burden estimates or any other aspect of
this collection of information,
including: the necessity and utility of
the proposed information collection for
the proper performance of the agency’s
functions, the accuracy of the estimated
burden, ways to enhance the quality,
utility and clarity of the information to
be collected, and the use of automated
collection techniques or other forms of
information technology to minimize the
information collection burden.
DATES: Comments must be received by
August 2, 2024.
ADDRESSES: When commenting, please
reference the applicable form number
(CMS–10434 #66) and the OMB control
number (0938–1188). To be assured
consideration, comments and
recommendations must be submitted in
any one of the following ways:
1. Electronically. You may send your
comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) that are accepting
comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: CMS–10434 #66/OMB
control number: 0938–1188, Room C4–
26–05, 7500 Security Boulevard,
Baltimore, Maryland 21244–1850.
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, please access the CMS PRA
website by copying and pasting the
following web address into your web
browser: https://www.cms.gov/
Regulations-and-Guidance/Legislation/
PaperworkReductionActof1995/
PRAListing.
FOR FURTHER INFORMATION CONTACT:
William N. Parham at (410) 786–4669.
SUPPLEMENTARY INFORMATION: Because of
system limitations, we are submitting
this generic collection of information
request on an interim basis under CMS–
10434 (OMB 0938–1188). At the
appropriate time we will move this
request under its proper place (CMS–
10398, OMB 0938–1148) and
subsequently remove it from CMS–
10434 to prevent duplication. The
public can monitor the status of such
activities at reginfo.gov.
Following is a summary of the use
and burden associated with the subject
information collection(s). More detailed
information can be found in the
VerDate Sep<11>2014
18:53 Jul 18, 2024
Jkt 262001
collection’s supporting statement and
associated materials (see ADDRESSES).
Generic Information Collection
1. Title of Information Collection:
Medicaid and Children’s Health
Insurance Program Eligibility Processing
Data Report; Type of Information
Collection Request: Revision of a
previously approved collection of
information request; Use: The COVID–
19 outbreak and implementation of
federal policies to address the public
health emergency disrupted routine
Medicaid, Children’s Health Insurance
Program (CHIP), and Basic Health
Program eligibility and enrollment
operations. Medicaid and CHIP
enrollment grew to historic levels due in
large part to the Medicaid continuous
enrollment condition that states
implemented as a condition of receiving
a temporary federal medical assistance
percentage (FMAP) increase under
section 6008 of the Families First
Coronavirus Response Act (Pub. L. 116–
127). In March 2022, CMS announced
that states were required to submit a
one-time baseline report and an ongoing
monthly report on renewal activities for
their total caseload of Medicaid and
CHIP enrollees prior to unwinding,
including the dispositions of renewals,
for a minimum of 14 months through
the submission of the ‘‘Unwinding Data
Report’’, hereinafter referred to as the
‘‘Eligibility Processing Data Report.’’
The Consolidated Appropriations Act
of 2023 (Pub. L. 117–238) (CAA, 2023)
ended the continuous enrollment
condition on March 31, 2023, and
required states to meet additional
conditions, including conducting
renewals consistent with federal
requirements or CMS approved
strategies, as a condition of receiving
increased FMAP through December
2023. The CAA, 2023 also required
states to submit and CMS to publicly
report data related to redeterminations
conducted between April 2023 through
June 2024. Some of the data outlined in
the CAA, 2023 are collected through the
Eligibility Processing Data Report.
States have faced challenges
completing the volume of work during
unwinding and restoring routine
operations, and many states continue to
process unwinding related renewals.
This package describes the Eligibility
Processing Data Report that states will
continue to submit to CMS on an
ongoing basis to support monitoring and
oversight efforts for the remainder of
states’ unwinding periods and to ensure
on-going compliance with federal
eligibility renewal requirements beyond
unwinding.
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
CMS is requiring mandatory state
reporting of their efforts to restore and
maintain eligibility and enrollment
operations and understand coverage
retention under the authority in sections
1902(a)(4)(A), 1902(a)(6) and 1902(a)(75)
of the Social Security Act (the Act), 42
CFR 431.16 to ensure proper and
efficient administration of the Medicaid
program, and section 2101(a) of the Act
to promote the administration of CHIP
in an effective and efficient manner.
CMS announced that the Eligibility
Processing Data Report collection will
continue beyond unwinding in State
Health Official Letter #24–002.
The Eligibility Processing Data Report
is a monthly report containing metrics
on application processing, renewals
initiated and the dispositions of those
renewals and fair hearings that states
submit using the existing Performance
Indicators portal for submission. States
can correct their data as needed. Given
that some renewals remain pending at
the end of a reporting month, states also
submit an update to each monthly
report to CMS in the fourth month after
the report is first due to provide more
complete renewal outcome data for the
renewal cohort reflected in the initial
report month. States started submitted
the monthly Eligibility Processing Data
Report to CMS in 2023 when they began
their unwinding periods.
In addition to changing the title of
this collection of information request, in
this July 2024 iteration we are also
extending the existing monthly data
collection and one-time update to the
renewal outcome data in each report for
the remainder of unwinding as well as
beyond unwinding. States will continue
to submit a monthly report in the
Eligibility Processing Data Report in the
submission portal. States will also
continue to provide a one-time update
to the data captured in the monthly
report concerning renewal outcomes
(metrics 5a, 5a(1), 5a(2), 5b, 5c, 5d) in
the submission portal. To provide the
updated report, states replace renewal
outcome data in the initial monthly
report in the portal and overwrite their
previously submitted data.
The Eligibility Processing Data Report
is accompanied by an excel workbook
that states may use for planning
purposes and a separate instruction
document (data specifications). The
excel workbook is a planning tool that
was provided to states in 2022 so they
could see all metrics in the report before
they had access to the Eligibility
Processing Data Report forms in the
submission portal. This workbook is not
submitted to CMS, nor are states
required to use it. While this workbook
is still available on www.Medicaid.gov
E:\FR\FM\19JYN1.SGM
19JYN1
Federal Register / Vol. 89, No. 139 / Friday, July 19, 2024 / Notices
for states, it is not updated for this 2024
iteration as states have access to the
metrics in the submission portal. The
data specifications document is updated
to reflect the changes made in this 2024
iteration of the Eligibility Processing
Data Report.
States submit the application
processing data in the Eligibility
Processing Data Report until states
complete working on pending
applications received before unwinding
began and report to CMS that zero
applications remain pending. When the
Eligibility Processing Data Report was
first launched, states previously
submitted a one-time baseline report
prior to submitting the monthly reports
and could make corrections to this
report as needed. The baseline report
form has remained available in the
submission portal. CMS is not extending
the use of the baseline report in this
2024 iteration since it was intended to
be a one-time submission. The baseline
report form will also be removed from
the submission portal in late summer/
early fall 2024.
Additionally, states submitted to CMS
a one-time State Report on Plans for
Prioritizing and Distributing Renewals
Following the End of the Medicaid
Continuous Enrollment Provisions
(‘‘State Renewals Report’’) that was used
to assess state’s plans for processing
renewals and mitigating against
inappropriate beneficiary coverage
losses when states begin restoring
routine Medicaid and CHIP operations
after the public health emergency. CMS
is not extending the use of this report in
this 2024 iteration.
Form Number: CMS–10434 #66 (OMB
control number: 0938–1188); Frequency:
Monthly; Affected Public: State, Local,
or Tribal Governments; Number of
Respondents: 56; Total Annual
Responses: 1,344; Total Annual Hours:
18,816. (For policy questions regarding
this collection contact: Shannon
Lovejoy at (410) 786–1718.)
William N. Parham III,
Director, Division of Information Collections
and Regulatory Impacts, Office of Strategic
Operations and Regulatory Affairs.
ddrumheller on DSK120RN23PROD with NOTICES1
[FR Doc. 2024–15882 Filed 7–18–24; 8:45 am]
BILLING CODE 4120–01–P
VerDate Sep<11>2014
18:53 Jul 18, 2024
Jkt 262001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2024–D–2682]
Pediatric Inflammatory Bowel Disease:
Developing Drugs for Treatment; Draft
Guidance for Industry; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a draft
guidance for industry entitled ‘‘Pediatric
Inflammatory Bowel Disease:
Developing Drugs for Treatment.’’ The
draft guidance was prepared by the
Division of Gastroenterology in the
Center for Drug Evaluation and Research
at FDA to help sponsors in the clinical
development of drugs to treat pediatric
patients with inflammatory bowel
disease. The draft guidance provides
FDA’s recommendations about the
necessary attributes of clinical studies
for drugs being developed for the
treatment of pediatric ulcerative colitis
or pediatric Crohn’s disease, including
study population, study design, efficacy
considerations, and safety assessments.
DATES: Submit either electronic or
written comments on the draft guidance
by September 17, 2024 to ensure that
the Agency considers your comment on
this draft guidance before it begins work
on the final version of the guidance.
ADDRESSES: You may submit comments
on any guidance at any time as follows:
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
58743
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2024–D–2682 for ‘‘Pediatric
Inflammatory Bowel Disease:
Developing Drugs for Treatment.’’
Received comments will be placed in
the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
E:\FR\FM\19JYN1.SGM
19JYN1
]]>Agencies
[Federal Register Volume 89, Number 139 (Friday, July 19, 2024)]
[Notices]
[Pages 58741-58743]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-15882]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[Document Identifier: CMS-10434 #66]
Medicaid and Children's Health Insurance Program (CHIP) Generic
Information Collection Activities: Proposed Collection; Comment Request
AGENCY: Centers for Medicare & Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: On May 28, 2010, the Office of Management and Budget (OMB)
issued Paperwork Reduction Act (PRA) guidance related to the
``generic'' clearance process. Generally, this is an expedited process
by which agencies may obtain OMB's approval of collection of
information requests that are ``usually voluntary, low-burden, and
uncontroversial collections,'' do not raise any substantive or policy
issues, and do not require policy or methodological review. The process
requires the submission of an overarching plan that defines the scope
of the individual collections that would fall under its umbrella. This
Federal Register notice seeks public comment on one or more of our
collection of information requests that we believe are generic and fall
within the scope of the
[[Page 58742]]
umbrella. Interested persons are invited to submit comments regarding
our burden estimates or any other aspect of this collection of
information, including: the necessity and utility of the proposed
information collection for the proper performance of the agency's
functions, the accuracy of the estimated burden, ways to enhance the
quality, utility and clarity of the information to be collected, and
the use of automated collection techniques or other forms of
information technology to minimize the information collection burden.
DATES: Comments must be received by August 2, 2024.
ADDRESSES: When commenting, please reference the applicable form number
(CMS-10434 #66) and the OMB control number (0938-1188). To be assured
consideration, comments and recommendations must be submitted in any
one of the following ways:
1. Electronically. You may send your comments electronically to
https://www.regulations.gov. Follow the instructions for ``Comment or
Submission'' or ``More Search Options'' to find the information
collection document(s) that are accepting comments.
2. By regular mail. You may mail written comments to the following
address: CMS, Office of Strategic Operations and Regulatory Affairs,
Division of Regulations Development, Attention: CMS-10434 #66/OMB
control number: 0938-1188, Room C4-26-05, 7500 Security Boulevard,
Baltimore, Maryland 21244-1850.
To obtain copies of a supporting statement and any related forms
for the proposed collection(s) summarized in this notice, please access
the CMS PRA website by copying and pasting the following web address
into your web browser: https://www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRAListing.
FOR FURTHER INFORMATION CONTACT: William N. Parham at (410) 786-4669.
SUPPLEMENTARY INFORMATION: Because of system limitations, we are
submitting this generic collection of information request on an interim
basis under CMS-10434 (OMB 0938-1188). At the appropriate time we will
move this request under its proper place (CMS-10398, OMB 0938-1148) and
subsequently remove it from CMS-10434 to prevent duplication. The
public can monitor the status of such activities at reginfo.gov.
Following is a summary of the use and burden associated with the
subject information collection(s). More detailed information can be
found in the collection's supporting statement and associated materials
(see ADDRESSES).
Generic Information Collection
1. Title of Information Collection: Medicaid and Children's Health
Insurance Program Eligibility Processing Data Report; Type of
Information Collection Request: Revision of a previously approved
collection of information request; Use: The COVID-19 outbreak and
implementation of federal policies to address the public health
emergency disrupted routine Medicaid, Children's Health Insurance
Program (CHIP), and Basic Health Program eligibility and enrollment
operations. Medicaid and CHIP enrollment grew to historic levels due in
large part to the Medicaid continuous enrollment condition that states
implemented as a condition of receiving a temporary federal medical
assistance percentage (FMAP) increase under section 6008 of the
Families First Coronavirus Response Act (Pub. L. 116-127). In March
2022, CMS announced that states were required to submit a one-time
baseline report and an ongoing monthly report on renewal activities for
their total caseload of Medicaid and CHIP enrollees prior to unwinding,
including the dispositions of renewals, for a minimum of 14 months
through the submission of the ``Unwinding Data Report'', hereinafter
referred to as the ``Eligibility Processing Data Report.''
The Consolidated Appropriations Act of 2023 (Pub. L. 117-238) (CAA,
2023) ended the continuous enrollment condition on March 31, 2023, and
required states to meet additional conditions, including conducting
renewals consistent with federal requirements or CMS approved
strategies, as a condition of receiving increased FMAP through December
2023. The CAA, 2023 also required states to submit and CMS to publicly
report data related to redeterminations conducted between April 2023
through June 2024. Some of the data outlined in the CAA, 2023 are
collected through the Eligibility Processing Data Report.
States have faced challenges completing the volume of work during
unwinding and restoring routine operations, and many states continue to
process unwinding related renewals. This package describes the
Eligibility Processing Data Report that states will continue to submit
to CMS on an ongoing basis to support monitoring and oversight efforts
for the remainder of states' unwinding periods and to ensure on-going
compliance with federal eligibility renewal requirements beyond
unwinding.
CMS is requiring mandatory state reporting of their efforts to
restore and maintain eligibility and enrollment operations and
understand coverage retention under the authority in sections
1902(a)(4)(A), 1902(a)(6) and 1902(a)(75) of the Social Security Act
(the Act), 42 CFR 431.16 to ensure proper and efficient administration
of the Medicaid program, and section 2101(a) of the Act to promote the
administration of CHIP in an effective and efficient manner. CMS
announced that the Eligibility Processing Data Report collection will
continue beyond unwinding in State Health Official Letter #24-002.
The Eligibility Processing Data Report is a monthly report
containing metrics on application processing, renewals initiated and
the dispositions of those renewals and fair hearings that states submit
using the existing Performance Indicators portal for submission. States
can correct their data as needed. Given that some renewals remain
pending at the end of a reporting month, states also submit an update
to each monthly report to CMS in the fourth month after the report is
first due to provide more complete renewal outcome data for the renewal
cohort reflected in the initial report month. States started submitted
the monthly Eligibility Processing Data Report to CMS in 2023 when they
began their unwinding periods.
In addition to changing the title of this collection of information
request, in this July 2024 iteration we are also extending the existing
monthly data collection and one-time update to the renewal outcome data
in each report for the remainder of unwinding as well as beyond
unwinding. States will continue to submit a monthly report in the
Eligibility Processing Data Report in the submission portal. States
will also continue to provide a one-time update to the data captured in
the monthly report concerning renewal outcomes (metrics 5a, 5a(1),
5a(2), 5b, 5c, 5d) in the submission portal. To provide the updated
report, states replace renewal outcome data in the initial monthly
report in the portal and overwrite their previously submitted data.
The Eligibility Processing Data Report is accompanied by an excel
workbook that states may use for planning purposes and a separate
instruction document (data specifications). The excel workbook is a
planning tool that was provided to states in 2022 so they could see all
metrics in the report before they had access to the Eligibility
Processing Data Report forms in the submission portal. This workbook is
not submitted to CMS, nor are states required to use it. While this
workbook is still available on www.Medicaid.gov
[[Page 58743]]
for states, it is not updated for this 2024 iteration as states have
access to the metrics in the submission portal. The data specifications
document is updated to reflect the changes made in this 2024 iteration
of the Eligibility Processing Data Report.
States submit the application processing data in the Eligibility
Processing Data Report until states complete working on pending
applications received before unwinding began and report to CMS that
zero applications remain pending. When the Eligibility Processing Data
Report was first launched, states previously submitted a one-time
baseline report prior to submitting the monthly reports and could make
corrections to this report as needed. The baseline report form has
remained available in the submission portal. CMS is not extending the
use of the baseline report in this 2024 iteration since it was intended
to be a one-time submission. The baseline report form will also be
removed from the submission portal in late summer/early fall 2024.
Additionally, states submitted to CMS a one-time State Report on
Plans for Prioritizing and Distributing Renewals Following the End of
the Medicaid Continuous Enrollment Provisions (``State Renewals
Report'') that was used to assess state's plans for processing renewals
and mitigating against inappropriate beneficiary coverage losses when
states begin restoring routine Medicaid and CHIP operations after the
public health emergency. CMS is not extending the use of this report in
this 2024 iteration.
Form Number: CMS-10434 #66 (OMB control number: 0938-1188);
Frequency: Monthly; Affected Public: State, Local, or Tribal
Governments; Number of Respondents: 56; Total Annual Responses: 1,344;
Total Annual Hours: 18,816. (For policy questions regarding this
collection contact: Shannon Lovejoy at (410) 786-1718.)
William N. Parham III,
Director, Division of Information Collections and Regulatory Impacts,
Office of Strategic Operations and Regulatory Affairs.
[FR Doc. 2024-15882 Filed 7-18-24; 8:45 am]
BILLING CODE 4120-01-P
